[go: up one dir, main page]

MX2019010594A - Beta-caseina a2 y prevencion de la inflamacion del intestino. - Google Patents

Beta-caseina a2 y prevencion de la inflamacion del intestino.

Info

Publication number
MX2019010594A
MX2019010594A MX2019010594A MX2019010594A MX2019010594A MX 2019010594 A MX2019010594 A MX 2019010594A MX 2019010594 A MX2019010594 A MX 2019010594A MX 2019010594 A MX2019010594 A MX 2019010594A MX 2019010594 A MX2019010594 A MX 2019010594A
Authority
MX
Mexico
Prior art keywords
casein
beta
inflammation
bowel
prevention
Prior art date
Application number
MX2019010594A
Other languages
English (en)
Other versions
MX391963B (es
Inventor
John Clarke Andrew
Suchin Trivedi Malav
Original Assignee
A2 Milk Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51989162&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019010594(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by A2 Milk Co Ltd filed Critical A2 Milk Co Ltd
Publication of MX2019010594A publication Critical patent/MX2019010594A/es
Publication of MX391963B publication Critical patent/MX391963B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de una composición para prevenir o reducir el riesgo de la inflamación del intestino en un animal, en donde la composición contiene beta-caseína y en donde la beta-caseína comprende al menos 50% en peso beta-caseína A2.
MX2019010594A 2013-05-31 2014-05-30 Beta-caseina a2 y prevencion de la inflamacion del intestino. MX391963B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829764P 2013-05-31 2013-05-31
PCT/NZ2014/000102 WO2014193248A1 (en) 2013-05-31 2014-05-30 Beta-casein a2 and prevention of inflammation of the bowel

Publications (2)

Publication Number Publication Date
MX2019010594A true MX2019010594A (es) 2019-10-15
MX391963B MX391963B (es) 2025-03-21

Family

ID=51989162

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010594A MX391963B (es) 2013-05-31 2014-05-30 Beta-caseina a2 y prevencion de la inflamacion del intestino.
MX2015016493A MX367794B (es) 2013-05-31 2014-05-30 Beta-caseína a2 y prevención de la inflamación del intestino.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015016493A MX367794B (es) 2013-05-31 2014-05-30 Beta-caseína a2 y prevención de la inflamación del intestino.

Country Status (19)

Country Link
US (2) US20160113997A1 (es)
EP (2) EP3003485B1 (es)
JP (2) JP6867158B2 (es)
KR (2) KR102402455B1 (es)
CN (2) CN105407971B (es)
AU (2) AU2014271423B2 (es)
BR (1) BR112015029987A8 (es)
CA (1) CA2913890C (es)
CL (1) CL2015003507A1 (es)
DK (1) DK3003485T3 (es)
ES (1) ES2742306T3 (es)
IL (2) IL242833B (es)
MX (2) MX391963B (es)
MY (1) MY179497A (es)
PH (2) PH12015502674B1 (es)
RU (1) RU2669553C2 (es)
SG (2) SG10201709509RA (es)
WO (1) WO2014193248A1 (es)
ZA (1) ZA201508983B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201709509RA (en) * 2013-05-31 2017-12-28 A2 Milk Co Ltd Beta-Casein A2 And Prevention Of Inflammation Of The Bowel
CA3214545A1 (en) * 2013-07-12 2015-01-15 The A2 Milk Company Limited Beta-casein a2 and reducing or preventing symptoms of lactose intolerance
GB2519101A (en) * 2013-10-09 2015-04-15 Nicoventures Holdings Ltd Electronic vapour provision system
US20170086481A1 (en) * 2014-06-03 2017-03-30 Abbott Laboratories Nutritional compositions comprising a lipophilic active ingredient
CN107708711A (zh) * 2015-05-22 2018-02-16 艾尔牛奶有限公司 β‑酪蛋白A2和抗氧化能力
WO2017003300A1 (en) * 2015-06-29 2017-01-05 The A2 Milk Company Limited A2 beta-casein and viscosity of milk products
JP7394527B2 (ja) 2016-03-30 2023-12-08 ズィ・エイツー・ミルク・カンパニー・リミテッド ベータカゼイン類および認知機能
US11925197B2 (en) 2016-09-30 2024-03-12 The A2 Milk Company Limited Beta-caseins and gut microbiota
JP7068277B2 (ja) * 2016-10-14 2022-05-16 エフ．ホフマン－ラ ロシュ アーゲー Ｅａａｔ３阻害剤としてのイミダゾール化合物
NL2019906B1 (en) * 2017-11-14 2019-05-20 Ausnutria Hyproca B V Composition comprising a2 b-casein and a vegetable fat mixture
WO2021003741A1 (zh) * 2019-07-11 2021-01-14 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
CN112205476A (zh) * 2019-07-11 2021-01-12 北京三元食品股份有限公司 β-酪蛋白A2、其组合物在促进双歧杆菌属增殖中的应用
CN115708530B (zh) * 2022-11-15 2024-08-09 北大荒完达山乳业股份有限公司 一种促进消化舒适性并稳定血糖的孕产妇配方奶粉及其制备方法
CN117322467A (zh) * 2023-10-11 2024-01-02 东北农业大学 A2β-酪蛋白在制备功能性食品中的应用
WO2026003044A1 (en) * 2024-06-25 2026-01-02 Ntd Labs, S.L. Casein hydrolysate for treating crohn's disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451368B1 (en) 1994-04-11 2002-09-17 New Zealand Dairy Board Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected
AU4266100A (en) * 1995-05-16 2000-10-12 Corran Norman Stuart Mclachlan Food product and process
DE69634831T2 (de) 1995-05-16 2006-06-29 A2 Corp. Ltd., Newmarket Nahrungsmittel und herstellungsverfahren
NZ306584A (en) * 1995-05-16 2000-02-28 Corran Norman Stuart Mclachlan Milk or dairy products derived from animals and which are free of beta casein
US6570060B2 (en) 1995-05-16 2003-05-27 Mclachlan Corran Norman Stuart Milk lacking β-casein A1
AU771754B2 (en) * 1999-06-29 2004-04-01 New Zealand Milk Institute Limited, The Prophylactic dietary supplement based on milk
NZ516712A (en) * 1999-06-29 2003-10-31 New Zealand Milk Inst Ltd Prophylactic dietary supplement based on milk
AU9037401A (en) 2000-09-08 2002-03-22 New Zealand Dairy Board Milk containing beta-casein with proline at position 67 does not aggravate neurological disorders
CA2444470A1 (en) * 2001-04-10 2002-10-24 Societe Des Produits Nestle S.A. Method and composition for prophylaxis of diabetes
US20060280802A1 (en) * 2002-10-04 2006-12-14 Campbell Julie H Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2
US7481127B2 (en) 2004-09-27 2009-01-27 Lester William T Continuously variable transmission using oscillating torque and one-way drives
IES20070714A2 (en) * 2006-10-06 2008-04-16 Kerry Group Services Int Ltd A milk protein composition and use thereof
US8871276B2 (en) * 2008-02-11 2014-10-28 Technion Research And Development Foundation Ltd. Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
TWI516269B (zh) * 2009-08-14 2016-01-11 禾伸堂生技股份有限公司 使用於炎症性腸疾病（ｉｂｄ）治療和預防之透明質酸混合物
SG10201709509RA (en) * 2013-05-31 2017-12-28 A2 Milk Co Ltd Beta-Casein A2 And Prevention Of Inflammation Of The Bowel
CA3214545A1 (en) * 2013-07-12 2015-01-15 The A2 Milk Company Limited Beta-casein a2 and reducing or preventing symptoms of lactose intolerance

Also Published As

Publication number Publication date
US20200179485A1 (en) 2020-06-11
MX2015016493A (es) 2016-08-18
CA2913890A1 (en) 2014-12-04
EP3542813A1 (en) 2019-09-25
SG11201509769QA (en) 2015-12-30
AU2018274937B2 (en) 2020-10-29
HK1222362A1 (en) 2017-06-30
EP3003485B1 (en) 2019-05-15
PH12019550096A1 (en) 2020-02-10
IL262302A (en) 2018-11-29
RU2669553C2 (ru) 2018-10-12
CL2015003507A1 (es) 2016-12-16
JP2019165746A (ja) 2019-10-03
MX367794B (es) 2019-09-06
CN112316116A (zh) 2021-02-05
IL262302B (en) 2021-02-28
JP7224242B2 (ja) 2023-02-17
DK3003485T3 (da) 2019-08-19
SG10201709509RA (en) 2017-12-28
JP2016520611A (ja) 2016-07-14
PH12015502674A1 (en) 2016-03-07
AU2014271423B2 (en) 2018-12-20
IL242833B (en) 2019-07-31
RU2018131733A (ru) 2018-11-08
CN105407971A (zh) 2016-03-16
PH12015502674B1 (en) 2020-02-21
MX391963B (es) 2025-03-21
MY179497A (en) 2020-11-09
ZA201508983B (en) 2017-11-29
EP3003485A4 (en) 2016-11-30
BR112015029987A2 (pt) 2017-07-25
BR112015029987A8 (pt) 2021-12-07
KR20160024884A (ko) 2016-03-07
WO2014193248A1 (en) 2014-12-04
RU2018131733A3 (es) 2021-10-29
KR102282972B1 (ko) 2021-07-28
ES2742306T3 (es) 2020-02-13
KR102402455B1 (ko) 2022-05-25
CN105407971B (zh) 2020-11-17
AU2018274937A1 (en) 2019-01-03
RU2015153113A (ru) 2017-07-05
US11911439B2 (en) 2024-02-27
EP3003485A1 (en) 2016-04-13
JP6867158B2 (ja) 2021-04-28
KR20210094674A (ko) 2021-07-29
US20160113997A1 (en) 2016-04-28
NZ714912A (en) 2021-06-25
CA2913890C (en) 2024-09-10
AU2014271423A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
MX2019010594A (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
CO2017005995A2 (es) Composiciones para el cuidado bucal y métodos de uso
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX385464B (es) Composiciones microencapsuladas de cannabinoides
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016001547A1 (es) Composiciones para el cuidado oral
CL2017000136A1 (es) Composiciones de azúcar para la formación de comprimidos por compresión directa
BR112017013770A2 (pt) composições de inibidor de nitrificação microencapsuladas
UY37153A (es) Sulfonilamidas sustituidas para combatir parásitos animales
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
CL2017000230A1 (es) Composición adhesiva
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
MX2017000829A (es) Composiciones de azucares para la formacion de comprimidos mediante compresion directa.
CL2015000537A1 (es) Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos.
MX2016016613A (es) Composicion en forma de particulas compactadas y su uso.
UA119441C2 (uk) Посилювачі водорозчинності на основі глікогену
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX2017007856A (es) Composicion para el cuidado bucal.
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
CL2015003736A1 (es) Sales de nalmefeno como medicamentos para reducir el consumo de alcohol o para prevenir el consumo excesivo de alcohol
CR20150352A (es) Nuevas composiciones antifúngicidas
MX2015017136A (es) Composicion para la administracion oral de magnesio, en asociacion con una composicion para tratar la diabetes tipo 2 o las complicaciones de la misma.